Pharmaceutical powerhouse Eli Lilly is reportedly on the verge of acquiring Kelonia Therapeutics, a Boston-based biotech company, in a transaction exceeding $2 billion. The Wall Street Journal broke the story Sunday, noting that an official announcement could arrive as soon as Monday, though the agreement isn’t finalized and could still collapse.
According to the Journal’s sources with knowledge of the negotiations, the deal structure may incorporate additional payments contingent upon Kelonia achieving specific clinical development benchmarks.
Shares of LLY climbed approximately 2.55% following the report.
Kelonia operates as a clinical-stage biotechnology firm specializing in CAR-T cell therapies — innovative cancer treatments that engineer a patient’s immune cells to target and eliminate malignant cells.
The biotech’s primary focus centers on multiple myeloma, a blood cancer affecting plasma cells. Kelonia’s innovative methodology seeks to streamline CAR-T treatment delivery by eliminating the requirement for chemotherapy and simplifying the traditionally complex cellular manufacturing processes.
This represents a significant advancement in the CAR-T sector, where treatment delivery challenges have historically created barriers to widespread adoption.
To date, Kelonia has secured approximately $60 million in investment capital. The company’s 2022 valuation stood at slightly over $100 million — making the rumored $2 billion-plus acquisition price represent substantial growth.
Neither Eli Lilly nor Kelonia provided responses to Reuters’ inquiries for comment outside of standard business hours.
Lilly maintains an established presence in cancer therapeutics. The company’s current oncology portfolio features treatments including Jaypirca and breast cancer medication Verzenio, alongside various pipeline candidates in development.
Acquiring Kelonia would significantly strengthen Lilly’s position in hematologic malignancies, representing one of oncology’s most rapidly expanding therapeutic areas.
This potential transaction aligns with recent corporate activity. Lilly has pursued an aggressive acquisition strategy, fueled by robust revenue streams from its blockbuster obesity drug Zepbound and diabetes medication Mounjaro.
Just last February, Lilly announced plans to acquire Orna Therapeutics in a deal valued at up to $2.4 billion. The Kelonia acquisition would mark another substantial transaction within a compressed timeframe.
Lilly has openly communicated its diversification objectives. The pharmaceutical company has been expanding into therapeutic areas including inflammatory bowel diseases, ophthalmologic conditions, oncology, and gene-editing technologies through strategic acquisitions and collaborative partnerships.
CAR-T therapies align perfectly with this strategic direction. The technology has demonstrated compelling efficacy in treating hematologic cancers, with multiple therapies receiving regulatory approval — yet manufacturing complexity and cost considerations continue presenting industry-wide challenges.
Kelonia’s streamlined methodology represents its key differentiator. Should the company successfully demonstrate clinical efficacy while reducing logistical complications, this competitive advantage justifies significant investment.
Lilly has not issued official confirmation regarding the transaction. The Wall Street Journal indicated negotiations could still dissolve before any formal announcement.
LLY shares traded up roughly 2.55% in response to the acquisition reports.
The post Eli Lilly (LLY) Eyes $2 Billion+ Acquisition of Cancer Therapy Startup Kelonia appeared first on Blockonomi.
